Related Experiment Videos
Human catecholamine sulfotransferase (SULT1A3) pharmacogenetics: functional genetic polymorphism.
Bianca A Thomae1, Oktay F Rifki, Michelle A Theobald
1Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Medical School-Mayo Clinic, Rochester, Minnesota 55905, USA.
Journal of Neurochemistry
|November 19, 2003
Summary
Genetic variations in sulfotransferase (SULT) 1A3, an enzyme crucial for catecholamine metabolism, were investigated. A specific SULT1A3 variant found in African-Americans significantly reduced enzyme activity and protein levels, suggesting ethnic-specific impacts on drug response and disease.
Area of Science:
- Pharmacogenomics
- Enzyme kinetics
- Human genetics
Background:
- Sulfotransferase (SULT) 1A3 plays a key role in metabolizing catecholamines and related drugs.
- Understanding inherited variations in SULT1A3 is crucial for studying human disease pathophysiology and drug response.
- Previous research has not fully elucidated the genetic landscape of SULT1A3 across different ethnic groups.
Purpose of the Study:
- To resequence the SULT1A3 gene in diverse populations to identify genetic variations.
- To characterize the functional impact of identified SULT1A3 variants on enzyme activity and protein stability.
- To explore the potential for ethnic-specific differences in catecholamine sulfation.
Main Methods:
- Resequencing of all coding exons, non-coding exons, splice junctions, and the 5'-flanking region of SULT1A3.
- DNA analysis of 60 African-American and 60 Caucasian-American subjects.
- Transient expression in COS-1 cells to assess enzyme activity and protein levels of SULT1A3 variants.
- Substrate kinetic studies to determine Km values for dopamine and 3'-phosphoadenosine 5'-phosphosulfate.
Main Results:
- Eight single nucleotide polymorphisms (SNPs) were found in African-American subjects and five in Caucasian-American subjects.
- A non-synonymous SNP (Lys234Asn) was identified exclusively in African-Americans, with a 4.2% allele frequency.
- The Lys234Asn variant exhibited significantly reduced enzyme activity (28% of wild-type) and protein levels (54% of wild-type).
- Kinetic studies showed no significant differences in Km values for dopamine or the cosubstrate between wild-type and variant enzymes.
- Accelerated proteasome-mediated degradation was identified as a contributing factor to the reduced protein level of the variant enzyme.
Conclusions:
- A specific SULT1A3 variant (Lys234Asn) identified in African-Americans leads to decreased enzyme activity and protein stability.
- This variant's reduced function is primarily due to accelerated protein degradation.
- The findings suggest the possibility of ethnic-specific inherited alterations in catecholamine sulfation, with implications for pharmacogenomics and disease susceptibility.